Background
==========

*Streptococcus pneumoniae* is a major cause of disease and death in the adult population \[[@B1]\]. Pneumococcus accounts for a range of medical conditions including invasive pneumococcal diseases (IPD) and non-invasive mucosal infections (non-IPD). The clinical and economic burden of pneumococcal disease in the adult population remains high \[[@B2],[@B3]\].

The process of preventing pneumococcal infections with vaccines has a long history, dating back to the beginning of 20th century. In Spain, a 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for adults with certain underlying risk factors as well as all individuals 65 years of age and older \[[@B4],[@B5]\].

PPV23 has had but limited impact on preventing IPD, while its effectiveness on mucosal disease (including community acquired pneumonia - CAP) is at the least controversial \[[@B6]\].

The routine use of pneumococcal conjugate vaccines, which induce a T-cell dependent immune response, has led to a significant reduction in vaccine-preventable cases of both IPD and non-IPD in young children \[[@B7],[@B8]\]. Conjugate vaccines not only prevent individual cases of disease directly but also indirectly by reducing disease transmission. Both effects benefit the health economic profile of these vaccines.

In 2010, a new 13-valent conjugate vaccine (PCV13) that widened the spectrum of the former 7-valent conjugate was licensed to reduce the incidence of pneumococcal disease in children. An adult indication for the prevention of pneumococcal disease caused by the serotypes included in the vaccine has recently been approved.

At present, there is no evidence available regarding the cost-effectiveness of adult pneumococcal immunization in the Spanish population. This efficiency, which is illustrated by the pharmacoeconomic data, is becoming increasingly important in Public Health decision making.

Several cost-effectiveness studies have recently been published analysing the economic implications of implementing an adult pneumococcal immunization programme with PCV13 \[[@B9],[@B10]\]. Comparisons between studies are difficult due to differences in methodology used and assumptions made.

In this context, the work by Rozenbaum et al. \[[@B9]\], adapted a former model developed by the authors to target PCV13 use in adults \>65 years of age in the Netherlands. The authors concluded that, with a wide variety of assumptions, including an effectiveness of 60% against IPD and non-IPD and compared to a no-vaccination strategy, there were incremental cost-effectiveness ratios (ICERs) varying from cost-savings to 50,676€/life year gained.

Additionally, Smith et al. \[[@B10]\] compared different PCV13 vaccination strategies in the adult population versus no vaccination or PPV23. After varying PCV13 effectiveness by age and patient risk, the authors concluded that, in the base case scenario (vaccinating at 65 years of age and in younger high-risk individuals) the cost per quality-adjusted life year (QALY) was USD 28,900 versus no vaccination, and that PCV13 was more efficient than PPV23.

Both publications took into account indirect effects (herd immunity) using a static approach due to the Markovian structure of the models used.

The aim of our study was to estimate the cost-effectiveness of pneumococcal vaccination targeting a 65-year-old cohort versus a no-vaccination strategy using a transmission-dynamic model. To address this, we analysed pneumococcal epidemiology in the adult Spanish population over 50 years of age (15,448,561 inhabitants) \[[@B11]\] and measured the clinical and economic consequences during the first 5 years.

Methods
=======

Model design
------------

Most of the published pharmacoeconomic models for infectious diseases use decision trees or Markovian chains \[[@B12]\]. As mentioned, these type of models assume a constant force of infection (per-susceptible rate of infection) during the analysed period and therefore they do not fully compute the effects of a vaccination programme \[[@B13]\]. However, the dynamic models used by epidemiologists \[[@B14]\] capture both direct effects from the reduction in the number of susceptible individuals and the indirect effect associated with the reduction of the number of contacts between susceptible and infected individuals. The implementation of a pneumococcal vaccination programme causes both types of effect because it directly protects vaccinated individuals and, at the same time, indirectly protects unvaccinated individuals by limiting the carriage and therefore the transmission of pneumococcus between individuals \[[@B15]\].

A deterministic *Susceptible → Infected → Susceptible* (SIS) model was used, in which individuals who are susceptible can become infected, after which they return to the susceptible group once they have recovered. The SIS model was calibrated to the epidemic behaviour of the pneumococcal bacterium. If a preventive campaign is implemented, the susceptible group will be reduced every year according to the number of individuals effectively vaccinated (Figure [1](#F1){ref-type="fig"}); thus, the number of infections between the susceptible and infected groups is also reduced.
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Differential equation models can be used to model this epidemic behaviour dynamically \[[@B16]-[@B18]\]. Contacts between infected and susceptible individuals are taken into account by multiplying their values at each point in time as ***\[I(t)·S(t)\]*** according to the following non-linear system of ordinary differential equations:

$$\left\{ \begin{array}{l}
{\frac{\mathit{dS}\left( t \right)}{\mathit{dt}} = - \beta\mspace{2mu}\cdot\mspace{2mu} I\left( t \right)\mspace{2mu}\cdot\mspace{2mu} S\left( t \right) + \gamma\mspace{2mu}\cdot\mspace{2mu} I\left( t \right) - V\left( t \right)\mspace{2mu}} \\
{\frac{\mathit{dI}\left( t \right)}{\mathit{dt}} = + \beta\mspace{2mu}\cdot\mspace{2mu} I\left( t \right)\mspace{2mu}\cdot\mspace{2mu} S\left( t \right) - \gamma\mspace{2mu}\cdot\mspace{2mu} I\left( t \right)\mspace{2mu}} \\
\end{array} \right)$$

where ***t*** = time measured in months; ***I(t) and S(t)*** = the number of infected and susceptible individuals, respectively, at each point in time *t*; ***β*** = the transmission coefficient; and ***γ*** = the coefficient of natural recovery. First order derivatives with respect to t, ***dI(t)/dt*** and ***dS(t)/dt,*** represent the instant rate of variation in time of the functions associated with the different population classes (infected and susceptible); ***V(t),*** shows the number of individuals who are vaccinated at each point in time *t*.

The coefficient of natural recovery *(γ)* is one indicator of the rate at which infected individuals again become susceptible; it depends on how long an individual remains infected, which is 30 days *(τ = 1 month)* according to some authors \[[@B19],[@B20]\]. Our model uses the month as the unit of time comprising each year; thus *γ* = 1/*τ* = 1. By applying a process of stepwise approximations, we estimated the transmission coefficient (*β=0.000010009257)* associated with the mean annual incidence rate of 563 pneumococcal infections per 100,000 individuals \> 50 years of age (Table [1](#T1){ref-type="table"}).

###### 

**Mean annual incidence (cases per 100,000)**\[[@B21]-[@B24]\]

                           **Pneumococcal disease**   **Cases**
  ----------------------- -------------------------- -----------
        **NON-IPD**         Hospitalized pneumonia     318.75
   Out-patient pneumonia            214.27           
          **IPD**             Primary bacteremia        8.10
          Empyema                    0.11            
        Meningitis                   2.67            
   Bacteremic pneumonia             18.83            
                             **Total contagions**      **563**

Adult pneumococcal disease incidence (IPD and non-IPD)
------------------------------------------------------

The pneumococcal diseases entered in this model were primary bacteremia, empyema, meningitis and bacteremic pneumonia (IPD), and hospitalized and out-patient pneumococcal pneumonia (non-IPD).

The pneumococcal disease incidence rate was calculated using the published number of hospitalized CAP cases in the Spanish population \>50 years of age over a 5-year period (447,670 CAP discharges from 2003 to 2007) \[[@B21]\]. For this model, it was estimated that 50% of CAP cases were caused by *Streptococcus pneumoniae*\[[@B22]\].

In addition, according to several authors, 40% of CAP cases in adults do not require hospitalization, and those were considered out-patient pneumococcal pneumonia \[[@B23]\]. Finally, based on published data, an incidence rate of 30 IPD cases per 100,000 individuals was used \[[@B24]\].

Pneumococcal force of infection
-------------------------------

The model associated the force of infection with the number of individuals infected at each point in time ***λ(t)= β·I(t)***. The transmission coefficient (***β***) represents the probability of a contact between a susceptible and an infected individual leading to transmission of the infection. Due to its high precision, a 4th order Runge--Kutta method was used to solve the differential equation system \[[@B25],[@B26]\]. Figure [2](#F2){ref-type="fig"} shows the proper adjustment between the historical series of infections and the series of values generated by the model.

![**Annual rate of pneumococcal infections\[**\[[@B21]\]**-**\[[@B26]\]**\].**](1471-2334-13-175-2){#F2}

The system deals with vaccination progressively according to the following functions:

$$V\left( t \right) = \quad\left\{ \begin{array}{l}
{0\mspace{45mu}\mathit{if}\quad 1 \leq \mathit{t} \leq 2} \\
{\quad\frac{V}{2}\qquad\mathit{if}\quad 2 < t \leq 4} \\
{\quad 0\mspace{45mu}\mathit{if}\quad 4 < t \leq 12} \\
\end{array} \right)$$

where ***V*** is the hypothetical number of individuals actually vaccinated in each annual campaign. The pneumococcal vaccine is co-administered together with the influenza vaccine, as recommended, for specific groups \[[@B27]\]. The time is measured in months, one year being the epidemiologic period to run the model.

According to the recommendations of the Spanish National Centre for Epidemiology, the epidemiologic year for influenza starts in August (month 1) and it concludes in August of the following year. The interval in which ***V(t)*** is not zero is the same as the interval associated with the vaccination campaign (October and November).

Population, vaccine effectiveness, serotype and vaccine coverage
----------------------------------------------------------------

The target population for the vaccination programme is the 65-year-old cohort, but consequences were measured in the population \>50 years of age. Although people enter the population \>50 years of age through aging or migration and people leave it because of death or migration, we assumed that the population \>50 years of age would not significantly change during the study period. Therefore the composition of the population \>50 years of age was not changed in the model. In the base case scenario, as in previous published studies \[[@B9]\], a weighted mean vaccine effectiveness of 58% for both IPD and non-IPD (mainly non-bacteremic pneumococcal pneumonia) was assumed. It was assumed that the vaccination programme would reach an annual coverage of 66%, which is similar to the 2009--10 influenza programme \[[@B28]\]. The proportion of IPD and non-IPD cases covered by the serotypes included in the PCV13 vaccine was assumed to be 60%, which is a little lower than the 66% serotype coverage rate reported for 2009 in the Madrid region for persons over 59 years of age \[[@B29]\].

Costs
-----

The costs associated with pneumococcal disease, in euros for the year 2010, were determined according to published data in the Spanish population \[[@B23],[@B24]\]. The cost of the vaccination programme was calculated using the official price of PCV13 \[[@B30]\] (Table [2](#T2){ref-type="table"}).

###### 

**Unit costs (€ 2010)** \[\[[@B23],[@B24],[@B30]\]\]

              **Concept**              **Cost**
  ----------------------------------- ----------
        Hospitalized pneumonia          1,983
         Out-patient pneumonia           250
          Primary bacteremia            4,093
                Empyema                 5,954
              Meningitis                11,202
         Bacteremic pneumonia           5,420
   Prevenar 13® exfactory price/dose    49,91

Sensitivity analysis
--------------------

In order to minimize model uncertainty, a sensitivity analysis was performed with two alternative scenarios. In those scenarios, vaccination coverage and vaccine effectiveness varied from 60% to 80% and from 40% to 75%, respectively, but serotype coverage remained unchanged.

Additionally, pneumococcal disease-related costs and discounts rates were also modified to broaden the sensitivity analysis spectrum, and those are described in Table [3](#T3){ref-type="table"}.

###### 

Sensitivity analysis parameters

                 **Parameters**  **Scenario**           
  ----------------------------- -------------- -------- --------
           Vaccination coverage    **66%**       60%      80%
            PCV13 Effectiveness    **58%**       40%      75%
              Serotype Coverage    **60%**       60%      60%
    Hospitalized pneumonia cost   **1,983**     1,785    2,181
     Out-patient pneumonia cost    **250**       225      275
        Primary bacteremia cost   **4,093**     3,684    4,502
                   Empyema cost   **5,954**     5,359    6,549
                Meningitis cost   **11,202**    10,082   12,322
      Bacteremic pneumonia cost   **5,420**     4,878    5,962
          Discount rate (costs)     **3%**        5%       0%

Programme effectiveness
-----------------------

All patients would receive a single dose of PCV13. The annual number of effectively vaccinated individuals was calculated based on vaccine effectiveness and serotype and vaccination coverage. So it varies within model scenarios as depicted in Table [4](#T4){ref-type="table"}\[[@B11]\]. PCV13 is considered safe and rarely causes any severe adverse event. Neither adverse events nor their related costs were considered in this model.

###### 

**Coverage of the pneumococcal vaccination programme**\[[@B11]\]

   **Scenario**   **Vaccinated annually**   **Effectively vaccinated annually**   **Effectively vaccinated five-yearly**
  -------------- ------------------------- ------------------------------------- ----------------------------------------
   Unfavorable            278,074                         66,738                                 333,689
     **Base**           **304,492**                     **105,963**                            **529,815**
    Favorable             370,766                         166,845                                834,223

Time horizon, perspective and estimated benefits
------------------------------------------------

Analyses were undertaken from the Spanish Public Healthcare System perspective. Only direct costs were estimated, and results were expressed as the number of pneumococcal infections avoided, as this is the primary outcome generated by the differential equation system of the epidemiological dynamic model. Both clinical and economic consequences were measured during the first 5 years. According to the published Spanish recommendations \[[@B31]\], the discount rate applied for costs was 3%.

Results
=======

Number of avoided infections
----------------------------

Implementation of a pneumococcal vaccination programme with PCV13 in a 65-year-old cohort would help to significantly reduce both the clinical and the economic burden caused by *Streptococcus pneumoniae*.

In the base case analysis, there would be a reduction of more than 125,000 pneumococcal cases compared to no vaccination (Table [5](#T5){ref-type="table"}).

###### 

Epidemiologic effect of the vaccination programme

       **Year**        **Estimated contagions**            
  ------------------- -------------------------- --------- ---------
           1                    86,049            84,040     2,008
           2                    86,512            76,316    10,196
           3                    86,976            63,957    23,018
           4                    87,439            49,435    38,004
           5                    87,902            35,223    52,680
   **Total 5 years**           434,878            308,972   125,906

Estimated cases of pneumococcal disease avoided include IPD and non-IPD (out-patient pneumococcal pneumonia and hospitalized pneumococcal pneumonia).

The number of cases averted grows over time due to the progressive accumulation of vaccinated individuals. As the number of vaccinated individuals increases, the number of susceptible individuals decreases, and therefore there is a reduction in contacts between infected and susceptible individuals. Averted cases of pneumococcal disease were mainly cases of hospitalized pneumococcal pneumonia, followed by out-patient pneumococcal pneumonia (Table [6](#T6){ref-type="table"}).

###### 

Clinical and economic effects of the vaccination programme

               **Results**                  ***Year***     **Five-year results**                                                        
  -------------------------------------- ---------------- ----------------------- ----------------- ----------------- ----------------- ------------------
            **Base scenario**                                                                                                                    
      Avoided hospitalized pneumonias         1,134                5,755               13,078            21,471            29,998             71,436
       Avoided outpatient pneumonias           762                 3,869                8,792            14,434            20,166             48,022
        Avoided primary bacteremias             31                  156                  313               572               686              1,758
             Avoided empyemas                   0                    2                    4                 8                 9                 24
            Avoided meningitis                  10                  51                   103               189               226               579
       Avoided bacteremic pneumonias            71                  363                  728              1,330             1,594             4,087
          **Avoided contagions**            **2,008**           **10,196**           **23,018**        **38,004**        **52,680**        **125,906**
    Hospitalized pneumonia cost savings     2,247,819           11,411,544           25,933,983        42,577,699        59,486,125        141,657,169
     Outpatient pneumonia cost savings       190,504              967,134             2,197,917         3,608,480         5,041,478         12,005,513
     Primary bacteremias cost savings        125,824              639,232             1,281,675         2,341,411         2,807,267         7,195,409
           Empyemas cost savings              2,486               12,628               25,319            46,254            55,457            142,145
          Meningitis cost savings            113,513              576,685             1,156,266         2,112,310         2,532,584         6,491,358
    Bacteremic pneumonias cost savings       387,336             1,967,803            3,945,487         7,207,762         8,641,848         22,150,236
     **Savings by all cases averted**     **3,067,481**       **15,575,025**       **34,540,648**    **57,893,917**    **78,564,759**    **189,641,830**
           Cost of vaccinations             15,197,172          15,197,172           15,197,172        15,197,172        15,197,172         75,985,862
            Net healthcare cost             12,129,691           −377,853            −19,343,475       −42,696,744       −63,367,587       −113,655,968
    **Discounted net healthcare cost**    **12,129,691**       **−366,848**        **−18,233,081**   **−39,073,569**   **−56,301,280**   **−101,845,087**

Introduction of a pneumococcal vaccination programme with PCV13 in a 65-year-old cohort would be a cost-saving measure. Vaccination costs would be offset by cost saving for avoided cases of pneumococcal disease. Programme savings would be mainly generated by averted cases of hospitalized pneumonia followed by averted cases of bacteremic pneumonia (Table [6](#T6){ref-type="table"}).

Sensitivity analysis
--------------------

In the sensitivity analysis, although many parameters were modified in favourable and unfavourable ways, results were minimally affected. Even in the worst case scenario, we found that globally 88,366 pneumococcal cases would be averted (divided into 83,848 non-IPD and 4,518 IPD cases). In this conservative scenario, PCV13 resulted in cost savings as of the third year after the start of the programme and continues going forward (Table [7](#T7){ref-type="table"}).

###### 

Sensitivity analysis results

               **Results**                  ***Year***     **Five-year results**                                                        
  -------------------------------------- ---------------- ----------------------- ----------------- ----------------- ----------------- ------------------
        **Unfavourable scenario**                                                                                                                
      Avoided hospitalized pneumonias          785                 3,749                8,690            14,925            21,993             50,141
       Avoided outpatient pneumonias           528                 2,520                5,841            10,033            14,784             33,707
        Avoided primary bacteremias             21                  102                  208               398               503              1,232
             Avoided empyemas                   0                    1                    3                 5                 7                 17
            Avoided meningitis                  7                   34                   69                131               166               406
       Avoided bacteremic pneumonias            49                  237                  484               924              1,169             2,863
          **Avoided contagions**            **1,390**            **6,643**           **15,294**        **26,417**        **38,621**         **88,366**
    Hospitalized pneumonia cost savings     1,400,564            6,691,314           15,508,174        26,637,024        39,250,376         89,487,451
     Outpatient pneumonia cost savings       118,698              567,092             1,314,325         2,257,501         3,326,488         7,584,104
     Primary bacteremias cost savings         78,398              374,823              766,424          1,464,809         1,852,303         4,536,757
           Empyemas cost savings              1,549                7,405               15,141            28,937            36,592             89,623
          Meningitis cost savings             70,727              338,147              691,432          1,321,482         1,671,060         4,092,848
    Bacteremic pneumonias cost savings       241,340             1,153,848            2,359,348         4,509,247         5,702,099         13,965,882
     **Savings by all cases averted**     **1,911,277**        **9,132,628**       **20,654,844**    **36,218,999**    **51,838,917**    **119,756,665**
           Cost of vaccinations             13,878,696          13,878,696           13,878,696        13,878,696        13,878,696         69,393,481
            Net healthcare cost             11,967,420           4,746,068           −6,776,147        −22,340,303       −37,960,221       −50,363,184
    **Discounted net healthcare cost**    **11,967,420**       **4,520,065**       **−6,146,165**    **−19,298,394**   **−31,229,968**   **−40,187,043**
         **Favourable scenario**                                                                                                                 
      Avoided hospitalized pneumonias         1,744                8,632               18,959            29,239            38,179             96,754
       Avoided outpatient pneumonias          1,172                5,803               12,745            19,656            25,666             65,042
        Avoided primary bacteremias             47                  234                  454               779               873              2,387
             Avoided empyemas                   1                    3                    6                11                12                 32
            Avoided meningitis                  16                  77                   150               257               288               787
       Avoided bacteremic pneumonias           110                  545                 1,055             1,811             2,029             5,550
          **Avoided contagions**            **3,090**           **15,294**           **33,369**        **51,753**        **67,047**        **170,552**
    Hospitalized pneumonia cost savings     3,804,001           18,829,047           41,355,130        63,780,008        83,280,575        211,048,761
     Outpatient pneumonia cost savings       322,391             1,595,771            3,504,867         5,405,386         7,058,069         17,886,484
     Primary bacteremias cost savings        212,934             1,054,733            2,043,798         3,507,357         3,930,174         10,748,996
           Empyemas cost savings              4,206               20,836               40,375            69,287            77,640            212,345
          Meningitis cost savings            192,099              951,530             1,843,818         3,164,172         3,545,617         9,697,236
    Bacteremic pneumonias cost savings       655,491             3,246,874            6,291,595        10,769,994        12,098,587         33,089,542
     **Savings by all cases averted**     **5,191,122**       **25,698,792**       **55,079,583**    **86,723,204**    **109,990,663**   **282,683,364**
           Cost of vaccinations             18,504,928          18,504,928           18,504,928        18,504,928        18,504,928         92,524,641
            Net healthcare cost             13,313,807          −7,193,863           −36,574,655       −68,218,276       −91,485,735       −190,158,723
    **Discounted net healthcare cost**    **13,313,807**      **−7,193,863**       **−36,574,655**   **−68,218,276**   **−91,485,735**   **−190,158,723**

Discussion
==========

The three scenarios analyzed in our dynamic model suggest that, after three years, the 65-year-old cohort pneumococcal vaccination campaign appears to be a cost-saving measure in Spain. The avoided cases of hospitalized pneumococcal pneumonia (bacteremic and non-bacteremic) are responsible for the majority of the cost savings.

Since the vaccination programme generates savings under all 3 scenarios studied and prevents cases of pneumococcal disease, calculating the cost-effectiveness and cost-utility ratio in terms of life years gained would have not provided additional information. Therefore estimation efforts concerning number of deaths prevented and impact on population quality of life, although interesting from a public health point of view, would have unnecessarily complicated the modelling without adding information to assist decision makers.

Strengths and weaknesses
------------------------

This is the first evaluation of a national adult pneumococcal immunization programme with PCV13 using a dynamic model. Compared to other techniques, the use of differential equations captures the indirect effect of the vaccination programme for estimating health outcomes. This model adjusts fairly well to the pattern of the infective agent in the study population. The sensitivity analysis also showed that the model results were robust to changes in the parameters analyzed. The model economic outcomes were minimally sensitive to changes in vaccination coverage and PCV13 effectiveness.

Modelling the epidemiological impact of pneumococcal vaccination in adults is challenging due to several elements that have an impact on intervention outcomes and required some assumptions. Cohort and population models highlight different aspects of the infectious disease process and, therefore, we have only answered part of the questions raised about pneumococcal vaccination implementation \[[@B32]\]. We estimated the unknown effectiveness of PCV13 in adults and tried to minimize its uncertainty by using a sensitivity analysis. Additionally, pneumococcal nasopharyngeal carriage and adult-to-adult transmission patterns are not yet well understood.

In Spain, PCV13 is only included in the National Immunization Programmes for infants in Madrid \[[@B33]\] (2+1, since June 2010 with 96.3% uptake) and Galicia (2+1, since January 2012); these regions account for 19% of the Spanish population of all ages. So the childhood vaccination coverage within the country is uneven. For this reason, the potential herd effect from vaccinating the paediatric population has not been taken into account in the present model.

On the other hand, a potential additional effect of PPV23 on IPD cases in adults older than 65 years of age was not taken into account because we introduce the remaining burden of disease into the model after its long-term use.

Another limitation is that we did not take into account the potential increase in pneumococcal disease caused by serotypes not included in the PCV13. As there is currently no data available on the emergence of non-PCV13 serotypes, such a scenario was impossible to model.

This analysis did not include mortality rates and disease sequelae from pneumococcal disease. Having not incorporated mortality in our study should be considered as a model limitation. On the other hand, the implementation of an immunization programme in adults would increase population life expectancy and patient quality of life, which would further increase the benefit associated with this intervention. Additionally, we did not include indirect costs as this study has adopted a healthcare system perspective, so the vaccine value could have been underestimated. Although our model did not take into account the impact of the vaccine on patient quality of life, it would be interesting to measure how invasive and non-invasive pneumococcal disease influences quality of life. An appropriate instrument would be the EQ-5D, already used for other diseases such as the influenza, in the Spanish context \[[@B34]\].

Conclusions
===========

In conclusion, despite the inherent limitations of this model, the analysis suggests that a 65-year-old cohort vaccination programme with PCV13 in Spain would avoid a large number of cases of pneumococcal disease over a 5-year period and would be a cost-saving measure from a healthcare system perspective.
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